Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020
31 July 2020 - 10:17PM
Business Wire
Company to provide update on its lead drug
candidate, GPX-001 for non-small cell lung cancer, and its
preclinical diabetes gene therapy candidate that may have the
potential to cure Type 1 and Type 2 diabetes
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing technologies for patients with cancer and diabetes,
announced today that the Company will present at the Proactive
Investors One2One Virtual Event on August 4, 2020.
Mr. Rodney Varner, Genprex’s Chairman and Chief Executive
Officer, will deliver a Company overview and provide updates on its
product pipeline, including its lead drug candidate, GPX-001
(formerly referred to as “Oncoprex™” immunogene therapy), which
received Fast Track Designation from the U.S. Food and Drug
Administration (FDA) for use in combination with AstraZeneca’s
Tagrisso® in late stage lung cancer patients with EGFR mutations
whose tumors progress on Tagrisso. Mr. Varner will also provide an
overview of the Company’s preclinical diabetes gene therapy
candidate that may have the potential to cure Type 1 and Type 2
diabetes.
Event: Proactive Investors One2One Virtual Event
Date: Tuesday, August 4, 2020 Time: 1:40 p.m. ET
Registration Link: https://bit.ly/2D3fpx7
The Proactive Investor One2One investor forums are designed for
private investors, private client brokers, fund managers, financial
institutions, hedge funds, buy and sell side analysts and
journalists.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The Company’s lead
product candidate, GPX-001 (quaratusugene ozeplasmid), is being
evaluated as a treatment for non-small cell lung cancer (NSCLC).
GPX-001 has a multimodal mechanism of action that has been shown to
interrupt cell signaling pathways that cause replication and
proliferation of cancer cells; re-establish pathways for apoptosis,
or programmed cell death, in cancer cells; and modulate the immune
response against cancer cells. GPX-001 has also been shown to block
mechanisms that create drug resistance. In January 2020, the U.S.
Food and Drug Administration granted Fast Track Designation for
GPX-001 for NSCLC in combination therapy with osimertinib
(AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose
tumors progressed after treatment with osimertinib alone. For more
information, please visit the Company’s web site at www.genprex.com
or follow Genprex on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of GPX-001, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including GPX-002, our gene therapy
in diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our product candidates; the timing and success at all of
obtaining FDA approval of GPX-001 and our other potential product
candidates including whether we receive fast track or similar
regulatory designations; costs associated with developing our
product candidates and whether patents will ever be issued under
patent applications that are the subject of our license agreements.
These and other risks and uncertainties are described more fully
under the caption “Risk Factors” and elsewhere in our filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200731005061/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2024 to May 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From May 2023 to May 2024